Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,050 recruiting studies in this area right now.
By phase
- Not applicable2,999
- Phase 21,056
- Phase 1792
- Phase 1/Phase 2437
- Phase 3435
- Phase 4233
- Phase 2/Phase 398
Top conditions
- Multiple Sclerosis330
- Multiple Myeloma327
- Asthma193
- Lymphoma178
- Rheumatoid Arthritis131
- Type 1 Diabetes130
- Atopic Dermatitis124
- Systemic Lupus Erythematosus119
- Acute Lymphoblastic Leukemia118
- HIV Infections106
- Chronic Lymphocytic Leukemia95
- Autoimmune Diseases77
- Follicular Lymphoma70
- Rheumatoid Arthritis (RA)68
- Diabetes Mellitus, Type 163
- Hodgkin Lymphoma63
- Leukemia63
- Mantle Cell Lymphoma62
Leading sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)97
- Institute of Hematology & Blood Diseases Hospital, China85
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris65
- AstraZeneca63
- M.D. Anderson Cancer Center58
- Novartis Pharmaceuticals58
- Mayo Clinic49
- City of Hope Medical Center48
- Memorial Sloan Kettering Cancer Center45
Where studies are running
- California496
- Maryland199
- Alabama178
- Florida149
- Arizona148
- Massachusetts116
- New York116
- Texas112
- Illinois83
- Colorado82
Recruiting studies6,050 total
- NCT07491523Recruiting
Adding anti-fibrotic to immunosuppression for scleroderma lung disease
This trial is testing whether adding an anti-fibrotic drug (a medicine that fights scarring) to two immunosuppressive drugs works better than the two drugs alone for people with scleroderma-related lung disease.
PátraiAges 18 years+ - NCT07490951Recruiting
CAR-T cell therapy for refractory autoimmune diseases
This trial tests a personalized cell therapy (CAR-T cells that target CD19 and BCMA proteins) for people with lupus, Sjogren's, scleroderma, dermatomyositis, antisynthetase syndrome, immune-mediated necrotizing myopathy, rheumatoid arthritis, or ANCA-associated vasculitis that has not responded to standard treatments. The goal is to see if this therapy can reduce disease activity.
Wuhan, HubeiAges 18–70 - NCT07489989RecruitingPhase 2
Combination therapy to boost CAR-T for B-cell lymphoma
This trial tests a new combination of drugs to make CAR-T cell therapy work better for people with certain types of B-cell lymphoma. It adds the drugs chidamide and a PD-1 inhibitor to the usual CAR-T treatment, aiming to improve response.
Beijing, Beijing MunicipalityAges 18–85 - NCT07489794Recruiting
Bladder Control and Pelvic Floor in MS
This study looks at how multiple sclerosis (MS) affects bladder control and pelvic floor muscles. It may help find better ways to manage urinary incontinence (leaking urine) in women with MS.
IstanbulAges 30–50 - NCT07490964Recruiting
Study of PCOS in women with type 1 diabetes
This study looks at the connection between type 1 diabetes and polycystic ovary syndrome (PCOS). It will compare women with both conditions to women with only diabetes and to women without either, to understand how PCOS affects diabetes management.
Madrid, MadridAges 18–45 - NCT07493109RecruitingPhase 3
Maintenance treatment for hepatitis B-related lymphoma after initial therapy
This trial tests whether the drug chidamide, taken after initial successful treatment, can help prevent relapse in people with a type of lymphoma (diffuse large B-cell lymphoma) who also have chronic hepatitis B. Participants must have achieved complete remission after six cycles of standard chemotherapy (R-CHOP).
Changchun, JilinAges 18–80 - NCT07493148RecruitingPhase 2
Chidamide and chemo for older adults with double-expressor DLBCL
This trial tests a combination of the targeted drug chidamide with a gentler chemotherapy (R-mini CHOP) followed by maintenance therapy for people aged 70 or older with a specific type of DLBCL that has both MYC and BCL2 proteins. It aims to improve outcomes while reducing side effects.
Changchun, JilinAges 70 years+ - NCT07491016Recruiting
Telitacicept plus baricitinib for hard-to-treat rheumatoid arthritis
This study tests a combination of two drugs (telitacicept and baricitinib) for people with stubborn rheumatoid arthritis that hasn't improved with other treatments. The goal is to see if this combination is safe and effective in reducing joint pain and inflammation.
Hangzhou, ZhejiangAges 18–85 - NCT07490925Recruiting
Breathing Machine Strategy to Protect the Heart in ARDS
This trial tests a special breathing machine strategy that uses pressure measurements from a small tube in your esophagus (food pipe) to protect your heart's right side while treating ARDS caused by pneumonia. It may help if you have severe lung failure and need a ventilator.
BeijingAges 18 years+ - NCT07497399RecruitingPhase 2
Testing a diabetes drug for weight loss in MS
This trial tests if a GLP-1 receptor agonist can help people with multiple sclerosis who have a high BMI. It may reduce inflammation and improve health.
Baltimore, MarylandAges 18–60 - NCT07490041RecruitingEarly Phase 1
CAR-NK cell therapy for refractory childhood rheumatic diseases
This trial is testing a new type of cell therapy (CAR-NK cells) that targets two markers on immune cells (CD19 and BCMA) to treat severe forms of childhood rheumatic diseases. It aims to see if this treatment is safe and can help when other medicines have failed.
Hangzhou, ZhejiangAges 5 years+ - NCT07492667Recruiting
Comparing new vs. old criteria for diagnosing multiple sclerosis
This trial compares two sets of diagnostic criteria (McDonald criteria 2024 vs. 2017) for multiple sclerosis in real-life settings. It aims to see which criteria work better in diagnosing MS in patients with symptoms or MRI findings that suggest the disease.
Ars-Laquenexy, LorraineAges Any age - NCT07495631Recruiting
Chemo + venetoclax + immunotherapy for adult ALL
This trial combines a kid-inspired chemotherapy backbone with a targeted pill (venetoclax) and immunotherapy (special antibodies) to treat adults with Ph-negative acute lymphoblastic leukemia (ALL). The goal is to use a more effective, less toxic approach developed for children.
Tianjin, Tianjin MunicipalityAges 14–60 - NCT07495059Recruiting
HIV prevention and care study for transgender women
This trial tests an adapted approach to improve HIV prevention and care for transgender women in Ho Chi Minh City. It aims to help participants stay healthy and access services.
Ho Chi Minh CityAges 16 years+ - NCT07494188Enrolling by invitation
Sleep screening for teens with type 1 diabetes
This study screens teenagers with type 1 diabetes for sleep problems and offers support to improve sleep, which may help with blood sugar control.
Aurora, ColoradoAges 11–17 - NCT07490587RecruitingPhase 2
Probiotic study for healthy infant growth and allergy prevention
This trial tests a probiotic supplement (Bifidobacterium animalis subsp. lactis XLTG11) to see if it helps infants grow better and have fewer allergies. It is for healthy babies up to 3 years old who are at higher risk for allergies.
Pudong, Shanghai MunicipalityAges birth–3 years - NCT07494565RecruitingPhase 2
Celecoxib plus standard chemo for CD5+ DLBCL
This trial tests whether adding celecoxib (an anti-inflammatory drug) to the standard R-CHOP chemotherapy regimen can improve outcomes for people with a specific, hard-to-treat type of diffuse large B-cell lymphoma (DLBCL) that is CD5-positive. It's for people who are newly diagnosed and have advanced disease.
Guangzhou, GuangdongAges 18–80 - NCT05281809RecruitingPhase 2
CAR T-cell therapy made locally for B-cell blood cancers
This Phase 2 trial tests a locally manufactured CAR T-cell treatment for certain B-cell lymphomas and B-ALL that have limited treatment options left. It may help your immune system attack cancer cells that carry the CD19 marker, potentially as a bridge to transplant for some patients.
Pittsburgh, PennsylvaniaAges 18–79 - NCT07492992Recruiting
Home trial of a smart insulin pump with monitoring for type 1 diabetes
This trial is testing a new automated insulin pump system that talks to your smartphone and lets the care team check on you from home. It helps people with type 1 diabetes better manage their blood sugar without extra trips to the clinic.
Cartagena, MurciaAges 18 years+ - NCT07496229RecruitingPhase 1/Phase 2
Testing a new drug combo for T-cell lymphoma
This trial is testing two drugs together: GW5282 and golidocitinib. It aims to see if this combination can help people with a type of T-cell lymphoma called PTCL. The trial is for patients who have already received other treatments or where standard options are limited.
Chongqing, Chongqing MunicipalityAges 18 years+ - NCT07491900RecruitingPhase 1
Study of HB2198 for lupus with moderate to severe symptoms
This trial tests a new drug called HB2198 to see if it can help people with moderate to severe lupus. It may be an option for those whose current treatments haven't worked well enough.
BrisbaneAges 18–65 - NCT07489911Recruiting
Real-world study of triple inhaler for uncontrolled asthma
This study tests a triple-inhaler called Trimbow for people whose asthma is not well controlled despite using other inhalers. The goal is to see if switching to Trimbow helps reduce asthma attacks and improve day-to-day breathing.
CeljeAges 18 years+ - NCT07493135RecruitingEarly Phase 1
IMV102 for relapsed/refractory multiple myeloma
This early-phase trial tests an experimental drug called IMV102 for people with multiple myeloma that has come back or stopped responding to at least 3 prior treatments. The study aims to see if IMV102 is safe and how well it works.
BeijingAges 18–80 - NCT07490613RecruitingPhase 1
Study of SHR-3836 for people with multiple myeloma
This trial tests a new drug called SHR-3836 for patients with multiple myeloma that has come back or stopped responding to treatment. The goal is to see if the drug is safe and how it works against the cancer.
Suzhou, JiangsuAges 18 years+
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,050 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,115 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.